Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents
Por:
Zamora, C, Riudavets, M, Anguera, G, Alserawan, L, Sullivan, I, Barba, A, Serra, J, Ortiz, MA, Gallardo, P, Perea, L, Gavira, J, Barnadas, A, Majem, M, Vidal, S
Publicada:
1 jun 2021
Ahead of Print:
1 ene 2021
Resumen:
Background Anti-PD-(L)1 blocking agents can induce immune-related adverse events (irAEs), which can compromise treatment continuation. Since circulating leukocyte-platelet (PLT) complexes contribute to inflammatory and autoimmune diseases, we aimed to analyze the role of these complexes as predictors of irAEs in non-small cell lung cancer (NSCLC) patients receiving anti-PD-(L)1. Materials and methods Twenty-six healthy donors (HD) and 87 consecutive advanced NSCLC patients treated with anti-PD-(L)1 were prospectively included. Percentages of circulating leukocyte-PLT complexes were analyzed by flow cytometry and compared between HD and NSCLC patients. The association of leukocyte-PLT complexes with the presence and severity of irAEs was analyzed. Results NSCLC patients had higher percentages of circulating leukocyte-PLT complexes. Higher percentages of monocytes with bound PLT (CD14 + PLT +) were observed in patients who received prior therapies while CD4 + T lymphocytes with bound PLT (CD4 + PLT +) correlated with platelets counts. The CD4 + PLT + high percentage group presented a higher rate of dermatological irAEs while the CD4 + PLT + low percentage group showed a higher rate of non-dermatological irAEs (p < 0.001). A lower frequency of grade >= 2 irAEs was observed in the CD4 + PLT + high percentage group (p < 0.05). Patients with CD4 + PLT + low and CD14 + PLT + high percentages presented a higher rate of grade >= 3 irAEs and predominantly developed non-dermatological irAEs (p < 0.01). Conclusions Our results suggest that circulating leukocyte-PLT complexes and the combination of CD4 + PLT + and CD14 + PLT + percentages can be used as a predictive biomarker of the development and severity of irAEs in advanced NSCLC patients receiving anti-PD-(L)1 agents.
Filiaciones:
Zamora, C:
Biomed Res Inst Sant Pau IIB St Pau, Grp Immunol Inflammatory Dis, Barcelona, Spain
Riudavets, M:
Hosp Santa Creu & Sant Pau, Dept Med Oncol, St Quinti 89, Barcelona 08041, Spain
Univ Autonoma Barcelona UAB, Dept Med, Barcelona, Spain
Anguera, G:
Hosp Santa Creu & Sant Pau, Dept Med Oncol, St Quinti 89, Barcelona 08041, Spain
Alserawan, L:
Hosp Santa Creu & Sant Pau, Dept Immunol, Barcelona, Spain
Sullivan, I:
Hosp Santa Creu & Sant Pau, Dept Med Oncol, St Quinti 89, Barcelona 08041, Spain
Barba, A:
Hosp Santa Creu & Sant Pau, Dept Med Oncol, St Quinti 89, Barcelona 08041, Spain
Serra, J:
Hosp Santa Creu & Sant Pau, Dept Med Oncol, St Quinti 89, Barcelona 08041, Spain
Ortiz, MA:
Biomed Res Inst Sant Pau IIB St Pau, Grp Immunol Inflammatory Dis, Barcelona, Spain
Gallardo, P:
Hosp Santa Creu & Sant Pau, Dept Med Oncol, St Quinti 89, Barcelona 08041, Spain
Perea, L:
Biomed Res Inst Sant Pau IIB St Pau, Grp Immunol Inflammatory Dis, Barcelona, Spain
Gavira, J:
Hosp Santa Creu & Sant Pau, Dept Med Oncol, St Quinti 89, Barcelona 08041, Spain
Barnadas, A:
Hosp Santa Creu & Sant Pau, Dept Med Oncol, St Quinti 89, Barcelona 08041, Spain
Majem, M:
Hosp Santa Creu & Sant Pau, Dept Med Oncol, St Quinti 89, Barcelona 08041, Spain
Vidal, S:
Biomed Res Inst Sant Pau IIB St Pau, Grp Immunol Inflammatory Dis, Barcelona, Spain
|